Logo
Rejuran S Acne Scar Treatment 1mL x 1 Syringe

Rejuran S Acne Scar Treatment 1mL x 1 Syringe

Rejuran

Skin booster
  • CE Marked polynucleotide dermal tissue stimulator within the Rejuran product family, certified under EU medical device regulations.
  • Approved by the Korean Ministry of Food and Drug Safety (MFDS) within the Rejuran range for regenerative skin treatment indications.
  • Manufactured under medical Device quality Management systems by PharmaResearch in South Korea.
Polynucleotide injectable for acne scars and atrophic scars

Description

Rejuran S Acne Scar Treatment 1mL x 1 Syringe is a specialised, polynucleotide (PN)–based injectable designed specifically for the repair and rejuvenation of atrophic acne scars and other depressed skin defects. As a more concentrated and viscous version of Rejuran Healer, it contains highly purified long-chain polynucleotides derived from salmon DNA, which have strong water-binding capacity and viscoelasticity suitable for scar reconstruction. Rejuran S acts both as a regenerative biostimulator and as a subtle filler: it creates a three-dimensional scaffold for collagen formation, plumps up sunken scars, and promotes healing and remodelling of the dermal structure. It is intended for intradermal injection by trained medical professionals and can be used alone or in combination with resurfacing procedures such as fractional lasers or radiofrequency for enhanced acne-scar improvement.

Bnefits

  • Targets atrophic acne scars and other depressed scars with a highly concentrated polynucleotide formula.
  • Fills and lifts sunken or depressed scars, leading to smoother, more even skin texture.
  • Long-chain polynucleotides derived from salmon DNA provide strong water-binding and viscoelastic properties for localised scar support.
  • Stimulates collagen synthesis and dermal remodelling, helping to rebuild and strengthen damaged skin structure.
  • Enhances overall skin quality in treated areas, improving firmness, elasticity and resilience.
  • Can be combined with fractional lasers, CO2 resurfacing or other scar therapies to synergistically improve acne-scar outcomes.
  • Biocompatible and biodegradable scaffold that is gradually broken down by the body while encouraging tissue regeneration.
  • Higher viscosity and gel-like texture compared with Rejuran Healer, allowing product to stay localised within dense scar tissue for longer-lasting effect.

Indications

  • Atrophic acne scars (e.g. rolling, boxcar and selected ice-pick scars as clinically appropriate).
  • Depressed surgical scars.
  • Post-traumatic or post-inflammatory depressed scars.
  • Localised skin depressions and contour defects.
  • Improvement of skin texture and quality in scarred or uneven areas.

Composition

  • Polynucleotides (PN, polydeoxyribonucleotide sodium) 2% (20 mg/ml) derived from salmon DNA.
  • Buffered aqueous solution suitable for intradermal injection (exact buffer components not publicly specified).
  • Water for injections.

Formulation

  • High-viscosity, transparent injectable gel based on long-chain polynucleotides.
  • Regenerative dermal tissue stimulator and scar-repair skin booster rather than a traditional hyaluronic acid filler.
  • More concentrated and viscous than Rejuran Healer to provide structural support in dense, scarred tissue.
  • Sterile, pyrogen-controlled injectable medical device supplied in a pre-filled syringe.
  • Intended for intradermal or very superficial subcutaneous injection by qualified healthcare professionals.

Packaging

  • Box containing 1 pre-filled 1 mL syringe of Rejuran S Acne Scar Treatment.
  • Syringe supplied in sterile blister packaging; one fine injection needle is typically included (needle gauge may vary by distributor, commonly around 30G).
  • Instructions for use (IFU) / product leaflet.
  • Traceability labels for inclusion in patient medical records, where provided.

Usage

  • For professional use only: Rejuran S must be administered by a licensed and appropriately trained medical practitioner experienced with injectable treatments and scar management.
  • Perform a full medical history and skin assessment, including scar type, depth and distribution; discuss expectations and obtain informed consent.
  • Cleanse and disinfect treatment areas thoroughly; topical anaesthetic may be applied according to clinic protocol.
  • Inject small aliquots intradermally at the base of atrophic scars, using serial puncture or micro-droplet technique with a fine needle (commonly around 30G).
  • Place micro-deposits directly within or just beneath each depressed scar to create a localised scaffold and induce collagen formation.
  • Typical treatment protocol involves approximately 3–4 sessions spaced about 3–4 weeks apart; number of sessions and intervals should be individualised based on clinical response and scar severity.
  • Rejuran S can be combined with fractional laser or radiofrequency resurfacing and subcision where indicated, with injection usually performed after or between these procedures according to the practitioner’s protocol.
  • Avoid intravascular injection: use correct depth and angle, inject slowly with low pressure, and aspirate cautiously where appropriate.
  • Post-treatment, mild massage may be applied to distribute the product evenly in the scar base if clinically appropriate.
  • Advise patients to avoid makeup on treated areas for several hours and to avoid sunbeds, intense sun exposure, extreme temperatures, saunas and strenuous exercise for at least 24 hours or according to local protocol.
  • Follow the official instructions for use (IFU) and local regulations for complete details on dosing, technique, indications, warnings and precautions.

Contraindications

  • Known hypersensitivity or allergy to polynucleotides, salmon-derived products, or any component of the formulation.
  • History of severe allergic reactions or anaphylaxis to injectable products.
  • Active skin infections, inflammatory lesions or dermatologic diseases (bacterial, viral such as herpes, or fungal) at or near the intended injection sites.
  • Autoimmune disease or immunocompromised status unless, after careful evaluation, the treating physician judges the benefits to outweigh the risks.
  • Bleeding disorders, coagulation abnormalities or concurrent use of anticoagulant or antiplatelet medications that significantly increase bleeding risk, unless appropriately assessed and managed by a physician.
  • Pregnancy and breastfeeding (generally not recommended due to insufficient safety data).
  • Patients under 18 years of age.
  • Presence of permanent fillers or foreign bodies in the same treatment area where there is risk of interaction, unless evaluated and approved by an experienced practitioner.
  • Any general contraindications to injectable aesthetic procedures as determined by the treating healthcare professional.

Adverse Effects

  • Common, usually mild and transient injection-site reactions such as redness (erythema), mild swelling or oedema, irritation, tenderness, or a feeling of tightness.
  • Localised heightened sensitivity or minor pain in the treated area, typically resolving within a few hours to a couple of days.
  • Small papules or bumps at injection sites, usually subsiding spontaneously over several days.
  • Minor bruising or haematoma at injection points.
  • Temporary skin irregularities or asymmetry, which may require adjustment or further treatment.
  • Rare delayed inflammatory or hypersensitivity reactions such as prolonged redness, swelling, induration or itching, requiring medical evaluation and possible treatment.
  • Infection at the injection site if aseptic technique is not strictly followed.
  • Very rare but serious complications, as with other injectable treatments, including inadvertent intravascular injection leading to tissue ischaemia or necrosis, or embolic events; such events require immediate emergency management by an appropriately trained physician.
  • Any unexpected, persistent or severe adverse event should be promptly assessed and managed according to clinical best practice and the official product guidance.

Storage Conditions

  • Store refrigerated between 2–8 °C unless otherwise specified on the product packaging.
  • Do not freeze.
  • Keep in the original packaging to protect from light and contamination until use.
  • Avoid exposure to direct sunlight and excessive heat.
  • Do not use after the expiry date printed on the packaging.
  • Use only if the syringe and packaging are intact and the solution appears clear and free from visible particles.
  • Single-use sterile syringe: do not resterilise and do not reuse any opened or partially used syringe.

Duration

Clinical improvements in scar appearance and skin texture typically build up over several weeks and are maintained for around 9\u201312 months or longer after a full course of approximately 3\u20134 sessions, depending on scar severity, individual healing response, combined treatments and lifestyle factors. Maintenance or top-up sessions can be performed at the clinician\u2019s discretion to sustain results.

Onset

Initial plumping and hydration of depressed scars may be visible within days of treatment, with more pronounced improvements in scar depth, texture and dermal quality developing progressively over 4\u20138 weeks as collagen synthesis and tissue repair occur and continue with successive sessions.

Browse more Skin booster

Top Treatments

Top Cities in the UK